COMPUTATIONAL VACCINE DESIGN - PowerPoint PPT Presentation

1 / 22
About This Presentation
Title:

COMPUTATIONAL VACCINE DESIGN

Description:

COMPUTATIONAL VACCINE DESIGN RAM SAMUDRALA ASSOCIATE PROFESSOR UNIVERSITY OF WASHINGTON How can we design vaccines based on conformational epitopes and protein ... – PowerPoint PPT presentation

Number of Views:187
Avg rating:3.0/5.0
Slides: 23
Provided by: Man89
Category:

less

Transcript and Presenter's Notes

Title: COMPUTATIONAL VACCINE DESIGN


1
COMPUTATIONAL VACCINE DESIGN RAM
SAMUDRALA ASSOCIATE PROFESSOR UNIVERSITY OF
WASHINGTON How can we design vaccines based on
conformational epitopes and protein structure
prediction simulations?
2
GENOME SEQUENCE TO PROTEIN AND PROTEOME
3
INTRODUCTION
  • Conformational epitopes are two or more nonlocal
    regions of an antigen that interact structurally
    at the atomic level, together with each other and
    with the antibody.
  • Majority of B-cell epitopes are conformational.
  • Protective antibodies recognize structural
    elements in the context of complete antigen
    structure.

4
PROBLEMS
  • Linear peptides corresponding to the epitopes are
    devoid of structural context of native antigen.
  • Immune evasion mechanisms
  • Conformational flexibility.
  • Steric masking.
  • Antigen variation.
  • Presence of immunodominant decoy elements.

5
RESEARCH DESIGN
  • Aim
  • Transform an immunological region (i.e., region
    which can induce antibody) to an antigenic region
    (i.e., region which can bind with antibody).
  • Objectives
  • Retaining the native structure of epitopes.
  • Presenting the epitopes exposed to aqueous
    environment.
  • Method
  • Computational design of chimeric constructs by
    grafting epitopes in soluble/stable scaffolds.

6

METHOD
Bayesian probabilities

  • Scaffold


  • Chimeric designed protein

Derive interatomic distances
Atom type
Distance bin
Atom type
7
APPLICATIONS
  • HIV
  • Influenza
  • Syphilis
  • Anthrax

8
HIV
  • HIV-1s extensive diversity is a major challenge
    for vaccine design strategies.
  • The presence of segments that are nearly
    invariant in all HIV-1 M group strongly suggests
    that these conserved elements are both obligatory
    for viral viability and are therefore potential
    Achilles Heel of the virus.
  • Our scaffold based vaccine design is based on
    conserved elements of viral spike protein gp120
    and gp41.

9
HIV
Epitopes in gp120 of HIV
10
Epitopes in gp41 of HIV
HIV
11
INFLUENZA
  • For Influenza, we are utilizing the epitopes in
    viral surface protein hemagglutinin(HA).
  • Hemagglutin is responsible for receptor binding
    and membrane fusion of viral particles.
  • We have selected 3 protective epitopes from HA1
    of Influenza A virus H3N2 A/Wuhan/359/95 strain.

12
INFLUENZA
Epitopes in hemagglutinin of Influenza A virus
H3N2
13
SYPHILIS
  • Syphilis is caused by Treponema pallidum subsp.
    pallidum (T.pallidum), a highly virulent,
    invasive and genetically intractable spirochete.
  • For Syphilis, our design is based on N-terminal
    region of outer membrane protein TprK, which has
    been shown to elicit opsonizing antibodies
    response.
  • We have utilized a combination of structure
    prediction methods, immunological assays and a
    support vector machine based method for analyzing
    amino acid composition (CBTOPE) for the
    determination of discontinuous epitopes in TprK.

14
TprK of Treponema palladium
SYPHILIS
15
SYPHILIS
Discontinuous epitope in TprK protein of
Treponema palladium
16
ANTHRAX
  • Anthrax is caused by Bacillus anthracis, a
    gram-positive, spore forming, and rod-shaped
    bacterium.
  • Anthrax toxin belongs to the family of bacterial
    AB toxins, composed of a single B subunit,
    protective antigen and two alternative A
    subunits edema factor and lethal factor.
  • Protective antigen (PA) is the dominant antigen
    in both natural and vaccine-induced immunity to
    anthrax infection.
  • We are exploiting the epitopes from receptor
    binding domain (Domain IV) of protective antigen.

17
Protective antigen of Bacillus anthracis
ANTHRAX
18
ANTHRAX
Discontinuous epitope in protective antigen
domain IV of Bacillus anthracis
19
Epitope in gp120
Epitope in chimeric construct
RESULTS
20
Epitope in hemagglutinin
Epitope in chimeric construct
RESULTS
21
ACKNOWLEDGEMENTS
  • Rob Braiser
  • Renee Ireton
  • Shu Feng
  • Sarunya Suebtragoon
  • Shing-Chung Ngan
  • Shyamala Iyer
  • Siriphan Manocheewa
  • Somsak Phattarasukol
  • Tianyun Liu
  • Vanessa Steinhilb
  • Vania Wang
  • Yi-Ling Cheng
  • Zach Frazier

22
ACKNOWLEDGEMENTS
  • Budget
  • US1 million/year total costs
Write a Comment
User Comments (0)
About PowerShow.com